This grant funds phase 1 clinical trials, including first-in-human studies, to validate innovative biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers. Proposals should finalize preclinical validation, consider drug repurposing, and engage patients in defining trial endpoints. The program supports multidisciplinary teams to generate early safety and efficacy evidence, facilitating further testing, commercialization, and improved patient access across EU and Associated Countries.
Eligible applicants must comply with admissibility, financial, and operational capacity conditions outlined in the Horizon Europe Work Programme General Annexes. Eligible countries include EU Member States and Associated Countries, with specific provisions for some non-EU/non-Associated countries. P
